🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

UPDATE 1-Canada signs deal with Abbott for Panbio COVID-19 antigen tests

Published 2020-10-06, 01:27 p/m

(Adds background)

OTTAWA, Oct 6 (Reuters) - Canada said on Tuesday that it had signed a deal with Abbott ABT.N to purchase up to 20.5 million Panbio COVID-19 antigen tests as Health Canada approved the device, the first of its kind in Canada.

The disposable swab test may help ease pressure on testing sites and labs in Ontario and Quebec, where cases are surging and some patients must wait a week or longer for results.

It works in 15 minutes, and is similar to Abbot's BinaxNOW, already on the market in the United States.

"These antigens tests will have a role to play in avoiding large cluster outbreaks, when results are needed quickly to avoid further spread of the virus," said Patty Hajdu, Canada's Health Minister, in the statement.

Federal officials said last week that they expected an antigen test to be approved soon. L1N2GQ14F

Canada was slow to approve the tests, already widely used in some other countries. Officials have said they are moving as quickly as they can without compromising safety. L2N2GJ161

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.